{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:12:02Z","timestamp":1790860322203,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejca.2009.04.005","type":"journal-article","created":{"date-parts":[[2009,5,5]],"date-time":"2009-05-05T09:07:56Z","timestamp":1241514476000},"page":"1877-1889","source":"Crossref","is-referenced-by-count":74,"title":["Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia"],"prefix":"10.1016","volume":"45","author":[{"given":"Edurne","family":"San Jos\u00e9-Eneriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jim\u00e9nez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cordeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Arqueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"G\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Mart\u00ednez-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Heiniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Roman-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.04.005_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Horita","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2009.04.005_bib2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","author":"Amarante-Mendes","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/emboj\/17.2.384","article-title":"Bim: a novel member of the Bcl-2 family that promotes apoptosis","volume":"17","author":"O\u2019Connor","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2009.04.005_bib5","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.04.005_bib6","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors","volume":"24","author":"Kuribara","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2009.04.005_bib7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"Essafi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib8","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.04.005_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2009.04.005_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6602008","article-title":"Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia","volume":"91","author":"Roman-Gomez","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2009.04.005_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib15","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/sj.onc.1209236","article-title":"ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia","volume":"25","author":"Agirre","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib16","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib17","doi-asserted-by":"crossref","first-page":"18811","DOI":"10.1074\/jbc.M301010200","article-title":"Activation of the ERK1\/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim","volume":"278","author":"Ley","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.04.005_bib18","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2003.08.166","article-title":"Cadherin-13, a mediator of calcium-dependent cell\u2013cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa","volume":"21","author":"Roman-Gomez","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.04.005_bib19","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1038\/sj.onc.1208866","article-title":"Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense\/antisense transcription and marks the progression of chronic myeloid leukemia","volume":"24","author":"Roman-Gomez","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib20","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1128\/MCB.21.3.854-864.2001","article-title":"Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors","volume":"21","author":"Shinjyo","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2009.04.005_bib22","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1073\/pnas.0438011100","article-title":"JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis","volume":"100","author":"Lei","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.04.005_bib23","doi-asserted-by":"crossref","first-page":"49511","DOI":"10.1074\/jbc.M208086200","article-title":"Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation","volume":"277","author":"Biswas","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.04.005_bib24","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1182\/blood-2006-09-047043","article-title":"Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia","volume":"109","author":"Roman-Gomez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/sj.leu.2404257","article-title":"Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome","volume":"20","author":"Roman-Gomez","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2009.04.005_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.2006.06131.x","article-title":"Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter","volume":"134","author":"San Jose-Eneriz","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2009.04.005_bib27","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1200\/JCO.2005.01.4944","article-title":"Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis","volume":"23","author":"Roman-Gomez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.04.005_bib28","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib29","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2009.04.005_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.04.005_bib31","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.04.005_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2019deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.04.005_bib33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909002494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909002494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T23:08:50Z","timestamp":1589756930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909002494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0959804909002494"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.04.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}